Among patients with nondiabetic CKD, SGLT2 inhibitors have favorable effects in IgA nephropathy, whereas their efficacy is limited in focal segmental glomerulosclerosis and uncertain in autosomal dominant polycystic kidney disease and autoimmune-related nephritis. The gene discussed is SLC5A2; the disease is chronic kidney disease.